Divisions of Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; The Wistar Institute, Philadelphia, PA 19104, USA.
The Wistar Institute, Philadelphia, PA 19104, USA; Ludwig Institute for Cancer Research, New York, NY 10017, USA.
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):43-50. doi: 10.1016/j.bbcan.2018.05.003. Epub 2018 May 20.
The MYC oncogene is commonly altered across human cancers. Distinct from the normal MYC proto-oncogene, which is under tight transcriptional, translational, and post-translational control, deregulated oncogenic MYC drives imbalanced, non-linear amplification of transcription that results in oncogenic 'stress.' The term 'stress' had been a euphemism for our lack of mechanistic understanding, but synthesis of many studies over the past decade provides a more coherent picture of oncogenic MYC driving metastable cellular states, particularly altered metabolism, that activate and depend on cellular stress response pathways to allow for continued growth and survival. Both deregulated metabolism and these stress response pathways represent vulnerabilities that can be exploited therapeutically.
MYC 癌基因在人类癌症中普遍发生改变。与正常的 MYC 原癌基因不同,正常的 MYC 原癌基因受到严格的转录、翻译和翻译后控制,失调的致癌 MYC 驱动转录的不平衡、非线性扩增,导致致癌“应激”。“应激”一词曾是我们缺乏机制理解的委婉说法,但过去十年的许多研究的综合提供了一个更连贯的画面,即致癌 MYC 驱动亚稳态细胞状态,特别是改变代谢,激活并依赖细胞应激反应途径,以允许持续生长和存活。失调的代谢和这些应激反应途径都代表了可以被治疗利用的弱点。